In 2023, the ADA updated the recommendation for standards of care in patients with CKD and diabetes to recommend the use of SGLT2 inhibitors even with urinary albumin ranging from normal to 200 mg/g creatinine (Grade B recommendation) following the EMPA-KIDNEY trial (40). Here, SLC5A2 is linked to diabetes mellitus.